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Colquhoun makes an important comment about reverse causality
in our study of active commuting.1 2 We excluded people with
reported prevalent disease at baseline but cannot exclude the
possibility that including those with subclinical or undiagnosed
disease at baseline could have influenced the findings. In the
manuscript we originally submitted we simply considered two
groups of commuters—active and non-active. We tried to
minimise the potential contribution of reverse causality by
undertaking a sensitivity landmark analysis, which excluded all
events occurring in the first year of follow-up. This did not alter
the main findings.
In the review process we were asked to consider commuting by
cycle and by foot separately and to consider mixed mode
commuting. This additional analysis strengthened the paper,
but having more groups reduced the number of events in each
group, leaving insufficient power to perform the landmark
analysis we undertook in the original version. This analysis will
be possible in future when more events have accrued. We
thought that we had mentioned reverse causality as a limitation
in the discussion, but on re-reading realised that we had not.
We should have done, and we thank Colquhoun for his valid
point.
We adjusted for a comprehensive range of potential confounders
in our analyses, but residual confounding is always a possibility
in observational studies, which we acknowledge in the paper.
Observational data cannot show causality; randomised controlled
trials (RCTs) are the gold standard for establishing causality.
But RCTs are not always feasible for answering research
questions of this nature, owing to the relatively low event rate
in the general population. For example, it took 23 years of
follow-up in the Da Qing RCT to show that lifestyle intervention
reduced risk of mortality from cardiovascular disease and all
causes.3 Shorter term RCTs, however, show clear evidence of
improvements in health biomarkers in those randomised to
active commuting.4 5
Buchinsky and others asked about the thresholds used to divide
walking and cycling commuters into long and short duration.6
This was based on the median weekly commuting distance for
each group, which was six miles a week for walkers and 30
miles a week for cyclists.
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